Current HIV ResearchCurrent HIV ResearchCurrent HIV Research1570-162X1873-4251Bentham Science64397210.2174/011570162X282739231222062830MedicineResearch ArticleThe Interrelationship between HIV Infection and COVID-19: A Review of the LiteratureWangYiyuinfo@benthamscience.netLaiYuinfo@benthamscience.netSchool of Clinical Medicine, Chengdu University of Traditional Chinese MedicineSchool of Basic Medicine, Chengdu University of Traditional Chinese Medicine0101202422161507012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://journals.eco-vector.com/1570-162X/article/view/643972

The Corona Virus Disease 2019 (COVID-19) pandemic resulting from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to significant morbidity and mortality in patients and put a strain on healthcare systems worldwide. The clinical characteristics and results of COVID-19 in immunosuppressed patients, such as people living with human immunodeficiency virus (PLWH), considered at higher risk of severe disease, are not well-characterized. Accumulated evidence indicates that COVID-19 and the human immunodeficiency virus (HIV) can interact in various ways. This review explored the similarities and differences in virology between SARS-CoV-2 and HIV, the effect of the COVID-19 vaccine on PLWH, the impact of the COVID-19 pandemic on PLWH care and prevention, and the influence of HIV-related factors on COVID-19. Discovering the potential link between HIV and COVID-19 may provide a novel way to avoid the factors of HIV and SARS-CoV-2 coinfection and advance future research.

Keywords: COVID-19HIVCoinfectionSARS-CoV-2PLWHepidemicvirusOrganization WH. HO Director-General’s opening remarks at the media briefing on COVID-19-11 March. Geneva, Switzerland 2020.Coronavirus disease (COVID-19) data. 2023.Data on the size of the HIV epidemic. 2021.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372(9635): 293-9. doi: 10.1016/S0140-6736(08)61113-7 PMID: 18657708Li M, Wang H, Tian L, et al. COVID-19 vaccine development: Milestones, lessons and prospects. Signal Transduct Target Ther 2022; 7(1): 146. doi: 10.1038/s41392-022-00996-y PMID: 35504917Menza TW, Capizzi J, Zlot AI, Barber M, Bush L. COVID-19 vaccine uptake among people living with HIV. AIDS Behav 2022; 26(7): 2224-8. doi: 10.1007/s10461-021-03570-9 PMID: 34994913Chun HM, Milligan K, Agyemang E, et al. A systematic review of COVID-19 vaccine antibody responses in people with HIV. Open Forum Infect Dis 2022; 9(11): ofac579. doi: 10.1093/ofid/ofac579 PMID: 36438620D’Souza G, Springer G, Gustafson D, et al. COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: The MACS/WIHS combined cohort study. HIV Res Clin Pract 2020; 21(5): 130-9. doi: 10.1080/25787489.2020.1844521 PMID: 33211636Spinelli MA, Jones BLH, Gandhi M. COVID-19 outcomes and risk factors among people living with HIV. Curr HIV/AIDS Rep 2022; 19(5): 425-32. doi: 10.1007/s11904-022-00618-w PMID: 35930187Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: A systematic review. HIV Med 2020; 21(9): 567-77. doi: 10.1111/hiv.12911 PMID: 32671970Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 among people living with HIV: A systematic review. AIDS Behav 2021; 25(1): 85-92. doi: 10.1007/s10461-020-02983-2 PMID: 32734438Prabhu S, Poongulali S, Kumarasamy N. Impact of COVID-19 on people living with HIV: A review. J Virus Erad 2020; 6(4): 100019. doi: 10.1016/j.jve.2020.100019 PMID: 33083001Duerr R, Crosse KM, Valero-Jimenez AM, Dittmann M. SARS-CoV-2 portrayed against HIV: Contrary viral strategies in similar disguise. Microorganisms 2021; 9(7): 1389. doi: 10.3390/microorganisms9071389 PMID: 34198973Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study. Chin Med J 2020; 133(9): 1015-24. doi: 10.1097/CM9.0000000000000722 PMID: 32004165Baltimore D. Expression of animal virus genomes. Bacteriol Rev 1971; 35(3): 235-41. doi: 10.1128/br.35.3.235-241.1971 PMID: 4329869Mahmoudabadi G, Phillips R. A comprehensive and quantitative exploration of thousands of viral genomes. eLife 2018; 7: e31955. doi: 10.7554/eLife.31955 PMID: 29624169Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: A brief overview. Ann Ist Super Sanita 2010; 46(1): 5-14. doi: 10.1590/S0021-25712010000100002 PMID: 20348614Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9. doi: 10.1038/s41586-020-2008-3 PMID: 32015508Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012; 2(11): a006965. doi: 10.1101/cshperspect.a006965 PMID: 23043157General Office of National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia. 2020; pp. 1-13.Rein A. RNA packaging in HIV. Trends Microbiol 2019; 27(8): 715-23. doi: 10.1016/j.tim.2019.04.003 PMID: 31085095Savastano A, Ibáñez de Opakua A, Rankovic M, Zweckstetter M. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nat Commun 2020; 11(1): 6041. doi: 10.1038/s41467-020-19843-1 PMID: 33247108Mattei S, Glass B, Hagen WJH, Kräusslich HG, Briggs JAG. The structure and flexibility of conical HIV-1 capsids determined within intact virions. Science 2016; 354(6318): 1434-7. doi: 10.1126/science.aah4972 PMID: 27980210Campbell EM, Hope TJ. HIV-1 capsid: The multifaceted key player in HIV-1 infection. Nat Rev Microbiol 2015; 13(8): 471-83. doi: 10.1038/nrmicro3503 PMID: 26179359Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci 2021; 41(6): 1037-51. doi: 10.1007/s11596-021-2395-1 PMID: 34241776Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020; 181(5): 1016-1035.e19. doi: 10.1016/j.cell.2020.04.035 PMID: 32413319Illanes-Álvarez F, Márquez-Ruiz D, Márquez-Coello M, Cuesta-Sancho S, Girón-González JA. Similarities and differences between HIV and SARS-CoV-2. Int J Med Sci 2021; 18(3): 846-51. doi: 10.7150/ijms.50133 PMID: 33437221Watts JM, Dang KK, Gorelick RJ, et al. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 2009; 460(7256): 711-6. doi: 10.1038/nature08237 PMID: 19661910Fung M, Babik JM. COVID-19 in immunocompromised hosts: What we know so far. Clin Infect Dis 2021; 72(2): 340-50. doi: 10.1093/cid/ciaa863 PMID: 33501974Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020; 92(4): 441-7. doi: 10.1002/jmv.25689 PMID: 31994742Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5 PMID: 31986264Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 2020; 201(4): 7-P8. doi: 10.1164/rccm.2014P7 PMID: 32004066Bangham CRM, McMichael AJ. Why the long latent period? Nature 1990; 348(6300): 388. doi: 10.1038/348388a0 PMID: 1978928Vaillant AJ, Gulick P. HIV disease StatPearls. StatPearls Publishing 2019.Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382(13): 1199-207. doi: 10.1056/NEJMoa2001316 PMID: 31995857Li L, Huang T, Wang Y, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020; 92(6): 577-83. doi: 10.1002/jmv.25757 PMID: 32162702Liu Y, Han J, Li X, et al. COVID-19 vaccination in people living with HIV (PLWH) in China: A cross sectional study of vaccine hesitancy, safety, and immunogenicity. Vaccines 2021; 9(12): 1458. doi: 10.3390/vaccines9121458 PMID: 34960204Duly K, Farraye FA, Bhat S. COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations. Am J Health Syst Pharm 2022; 79(2): 63-71. doi: 10.1093/ajhp/zxab344 PMID: 34455440Vasan S, Pitisuttithum P. Vaccine development lessons between HIV and COVID-19. Lancet Infect Dis 2021; 21(6): 759-61. doi: 10.1016/S1473-3099(21)00274-7 PMID: 34051181Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557Han X, Yu X, Han Y, et al. Safety and immunogenicity of inactivated COVID-19 vaccines among people living with HIV in China. Infect Drug Resist 2022; 15: 2091-100. doi: 10.2147/IDR.S353127 PMID: 35480056Kang L, Shang W, Gao P, Wang Y, Liu J, Liu M. Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis. Vaccines 2022; 10(9): 1569. doi: 10.3390/vaccines10091569 PMID: 36146647Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 vaccine hesitancy among french people living with HIV. Vaccines 2021; 9(4): 302. doi: 10.3390/vaccines9040302 PMID: 33804808Bogart LM, Ojikutu BO, Tyagi K, et al. COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among black americans living with HIV. J Acquir Immune Defic Syndr 2021; 86(2): 200-7. doi: 10.1097/QAI.0000000000002570 PMID: 33196555Yao Y, Chai R, Yang J, et al. Reasons for COVID-19 vaccine hesitancy among chinese people living with HIV/AIDS: Structural equation modeling analysis. JMIR Public Health Surveill 2022; 8(6): e33995. doi: 10.2196/33995 PMID: 35486810Kaida A, Brotto LA, Murray MCM, et al. Intention to receive a COVID-19 vaccine by HIV status among a population-based sample of women and gender diverse individuals in British Columbia, Canada. AIDS Behav 2022; 26(7): 2242-55. doi: 10.1007/s10461-022-03577-w PMID: 35020094Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021; 384(23): 2187-201. doi: 10.1056/NEJMoa2101544 PMID: 33882225Logunov DY, Livermore DM, Ornelles DA, et al. COVID-19 vaccination and HIV-1 acquisition. Lancet 2022; 399(10333): e34-5. doi: 10.1016/S0140-6736(22)00332-4 PMID: 35397866Ten threats to global health in 2019 2019.Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020; 323(13): 1239-42. doi: 10.1001/jama.2020.2648 PMID: 32091533COVID-19 vaccines and HIV 2021.Frescura L, Godfrey-Faussett P, Feizzadeh A A, El-Sadr W, Syarif O, Ghys PD. Achieving the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One 2022; 17(8): e0272405. doi: 10.1371/journal.pone.0272405 PMID: 35925943Guaraldi G, Milic J, Martinez E, et al. Human immunodeficiency virus (HIV) care models during the coronavirus disease 2019 (COVID-19) era. Clin Infect Dis 2021; 73(5): e1222-7. doi: 10.1093/cid/ciaa1864 PMID: 34492689Roy K, Himelfarb A, Karrah K, et al. The social, behavioral, and ethical modalities of COVID-19 on HIV care in South Africa: A systematic review. Int J Environ Res Public Health 2022; 19(15): 9766. doi: 10.3390/ijerph19159766 PMID: 35955119Kowalska JD, Skrzat-Klapaczyńska A, Bursa D, et al. HIV care in times of the COVID-19 crisis - Where are we now in Central and Eastern Europe? Int J Infect Dis 2020; 96: 311-4. doi: 10.1016/j.ijid.2020.05.013 PMID: 32413608Qiao S, Yang X, Sun S, et al. Challenges to HIV service delivery and the impacts on patient care during COVID-19: perspective of HIV care providers in Guangxi, China. AIDS Care 2021; 33(5): 559-65. doi: 10.1080/09540121.2020.1849532 PMID: 33242981Disruption in HIV, Hepatitis and STI services due to COVID-19 2020.Sun S, Hou J, Chen Y, Lu Y, Brown L, Operario D. Challenges to HIV care and psychological health during the COVID-19 pandemic among people living with HIV in China. AIDS Behav 2020; 24(10): 2764-5. doi: 10.1007/s10461-020-02903-4 PMID: 32382824Pinto RM, Park S. COVID-19 pandemic disrupts HIV continuum of care and prevention: Implications for research and practice concerning community-based organizations and frontline providers. AIDS Behav 2020; 24(9): 2486-9. doi: 10.1007/s10461-020-02893-3 PMID: 32347403Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: A syndemic perspective. AIDS Behav 2020; 24(8): 2244-9. doi: 10.1007/s10461-020-02871-9 PMID: 32303925Krakower D, Solleveld P, Levine K, Mayer K. Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center. J Int AIDS Soc 2020; 176-7.Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV treatment in sub-Saharan Africa during COVID-19. J Int AIDS Soc 2021; 24(6): e25704. doi: 10.1002/jia2.25704 PMID: 34105884Jewell BL, Mudimu E, Stover J, et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: Results from multiple mathematical models. Lancet HIV 2020; 7(9): e629-40. doi: 10.1016/S2352-3018(20)30211-3 PMID: 32771089Holmes EA, O’Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science. Lancet Psychiatry 2020; 7(6): 547-60. doi: 10.1016/S2215-0366(20)30168-1 PMID: 32304649Shin S, Muñoz M, Espiritu B, et al. Psychosocial impact of poverty on antiretroviral nonadherence among HIV-TB coinfected patients in Lima, Peru. J Int Assoc Physicians AIDS Care (Chic) 2008; 7(2): 74-81. doi: 10.1177/1545109708315326 PMID: 18319510Wu DY, Munoz M, Espiritu B, et al. Burden of depression among impoverished HIV-positive women in Peru. J Acquir Immune Defic Syndr 2008; 48(4): 500-4. doi: 10.1097/QAI.0b013e31817dc3e9 PMID: 18614919Zafra-Tanaka JH, Ticona-Chavez E. Stigma related to HIV/AIDS associated with adherence to antiretroviral therapy in patients of a public hospital in Lima, Peru 2014. Rev Peru Med Exp Salud Publica 2016; 33(4): 625-32. doi: 10.17843/rpmesp.2016.334.2544 PMID: 28327830Earnshaw VA, Bogart LM, Laurenceau JP, et al. Internalized HIV stigma, ART initiation and HIV -1 RNA suppression in South Africa: Exploring avoidant coping as a longitudinal mediator. J Int AIDS Soc 2018; 21(10): e25198. doi: 10.1002/jia2.25198 PMID: 30362662Budak JZ, Scott JD, Dhanireddy S, Wood BR. The impact of COVID-19 on HIV care provided via telemedicine-past, present, and future. Curr HIV/AIDS Rep 2021; 18(2): 98-104. doi: 10.1007/s11904-021-00543-4 PMID: 33616811Bell N, Bracchi M, Dalla Pria A, Nelson M, Boffito M. Indirect human immunodeficiency virus morbidity and mortality due to coronavirus disease 2019. Clin Infect Dis 2021; 73(10): 1947-9. doi: 10.1093/cid/ciab128 PMID: 33580253Mehta SA, Rana MM, Motter JD, et al. Incidence and outcomes of COVID-19 in kidney and liver transplant recipients with HIV: Report from the national hope in action consortium. Transplantation 2021; 105(1): 216-24. doi: 10.1097/TP.0000000000003527 PMID: 33165238Nagarakanti SR, Okoh AK, Grinberg S, Bishburg E. Clinical outcomes of patients with COVID-19 and HIV co-infection. J Med Virol 2021; 93(3): 1687-93. doi: 10.1002/jmv.26533 PMID: 32949148Waters LJ, Pozniak AL. COVID-19 death in people with HIV: Interpret cautiously. Lancet HIV 2021; 8(1): e2-3. doi: 10.1016/S2352-3018(20)30332-5 PMID: 33316210Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 2021; 8(1): e24-32. doi: 10.1016/S2352-3018(20)30305-2 PMID: 33316211Looha MA, Taraghikhah N, Amini M, et al. The impact of HIV on the risk of COVID-19 death among hospitalized patients. Hum Antibodies 2023; 30(4): 165-75. doi: 10.3233/HAB-220011 PMID: 36617778Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One 2020; 15(8): e0238215. doi: 10.1371/journal.pone.0238215 PMID: 32845926Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. J Med Virol 2021; 93(4): 2385-95. doi: 10.1002/jmv.26740 PMID: 33331656Venturas J, Zamparini J, Shaddock E, et al. Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19. J Infect 2021; 83(2): 217-27. doi: 10.1016/j.jinf.2021.05.020 PMID: 34051225Diagnoses of HIV Infection in the United States and Dependent Areas 2016 2017.Islam JY, Madhira V, Sun J, et al. Racial disparities in COVID-19 test positivity among people living with HIV in the United States. Int J STD AIDS 2022; 33(5) doi: 10.1177/09564624221074468 PMID: 35306931Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One 2011; 6(8): e17502. doi: 10.1371/journal.pone.0017502 PMID: 21826193Varshney K, Ghosh P, Stiles H, Iriowen R. Risk factors for COVID-19 mortality among people living with HIV: A scoping review. AIDS Behav 2022; 26(7): 2256-65. doi: 10.1007/s10461-022-03578-9 PMID: 35024992Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584(7821): 430-6. doi: 10.1038/s41586-020-2521-4 PMID: 32640463Etienne N, Karmochkine M, Slama L, et al. HIV infection and COVID-19: Risk factors for severe disease. AIDS 2020; 34(12): 1771-4. doi: 10.1097/QAD.0000000000002651 PMID: 32773476Pan D, Sze S, Minhas JS, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine 2020; 23: 100404. doi: 10.1016/j.eclinm.2020.100404 PMID: 32632416Crepaz N, Dong X, Wang X, Hernandez AL, Hall HI. Racial and ethnic disparities in sustained viral suppression and transmission risk potential among persons receiving HIV care - United States, 2014. MMWR Morb Mortal Wkly Rep 2018; 67(4): 113-8. doi: 10.15585/mmwr.mm6704a2 PMID: 29389918Simard EP, Fransua M, Naishadham D, Jemal A. The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med 2012; 172(20): 1591-8. doi: 10.1001/archinternmed.2012.4508 PMID: 23045164Simoni JM, Huh D, Wilson IB, et al. Racial/Ethnic disparities in ART adherence in the United States: Findings from the MACH14 study. J Acquir Immune Defic Syndr 2012; 60(5): 466-72. doi: 10.1097/QAI.0b013e31825db0bd PMID: 22595873Millett GA. New pathogen, same disparities: Why COVID‐19 and HIV remain prevalent in U.S. Communities of colour and implications for ending the HIV epidemic. J Int AIDS Soc 2020; 23(11): e25639. doi: 10.1002/jia2.25639 PMID: 33222424Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20. doi: 10.1056/NEJMoa2002032 PMID: 32109013Jiang M, Guo Y, Luo Q, et al. T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis 2020; 222(2): 198-202. doi: 10.1093/infdis/jiaa252 PMID: 32379887Zhang H, Wu T. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis. J Infect 2020; 81(3): e82-4. doi: 10.1016/j.jinf.2020.06.036 PMID: 32569604Ho H, Peluso MJ, Margus C, et al. Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency virus. J Infect Dis 2021; 223(3): 403-8. doi: 10.1093/infdis/jiaa380 PMID: 32601704Tesoriero JM, Swain CAE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open 2021; 4(2): e2037069. doi: 10.1001/jamanetworkopen.2020.37069 PMID: 33533933Davies M-A. HIV and risk of COVID-19 death: A population cohort study from the western cape province, South Africa. MedRxiv 2020; 2020.07. doi: 10.1101/2020.07.02.20145185del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: A cohort study. Ann Intern Med 2020; 173(7): 536-41. doi: 10.7326/M20-3689 PMID: 32589451Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol 2020; 20(6): 363-74. doi: 10.1038/s41577-020-0311-8 PMID: 32346093Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382(19): 1787-99. doi: 10.1056/NEJMoa2001282 PMID: 32187464Bertagnolio S, Thwin SS, Silva R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO global clinical platform of COVID-19. Lancet HIV 2022; 9(7): e486-95. doi: 10.1016/S2352-3018(22)00097-2 PMID: 35561704Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015; 116: 76-84. doi: 10.1016/j.antiviral.2015.01.011 PMID: 25666761Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50. doi: 10.1038/d41573-020-00016-0 PMID: 32127666Chan JFW, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212(12): 1904-13. doi: 10.1093/infdis/jiv392 PMID: 26198719Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; 323(15): 1488-94. doi: 10.1001/jama.2020.3204 PMID: 32125362Han W, Quan B, Guo Y, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol 2020; 92(5): 461-3. doi: 10.1002/jmv.25711 PMID: 32073161Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020; 95: 183-91. doi: 10.1016/j.ijid.2020.03.013 PMID: 32173576Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13. doi: 10.1016/S0140-6736(20)30211-7 PMID: 32007143Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253: 117592. doi: 10.1016/j.lfs.2020.117592 PMID: 32222463Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323(20): 2052-9. doi: 10.1001/jama.2020.6775 PMID: 32320003Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort. Lancet HIV 2020; 7(8): e554-64. doi: 10.1016/S2352-3018(20)30164-8 PMID: 32473657Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: Summary of the data and responses to date. Curr Opin HIV AIDS 2021; 16(1): 63-73. doi: 10.1097/COH.0000000000000659 PMID: 33186229Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: A single-arm substudy of a phase 2/3 clinical trial. Lancet HIV 2021; 8(8): e474-85. doi: 10.1016/S2352-3018(21)00103-X PMID: 34153264Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslén M, Björkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One 2017; 12(7): e0180761. doi: 10.1371/journal.pone.0180761 PMID: 28683128Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85(10): 4828-40. doi: 10.1128/JVI.00198-11 PMID: 21389135Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 45(5): 483-93. doi: 10.1097/QAI.0b013e3180654836 PMID: 17496565Stover J, Kelly SL, Mudimu E, et al. The risks and benefits of providing HIV services during the COVID-19 pandemic. PLoS One 2021; 16(12): e0260820. doi: 10.1371/journal.pone.0260820 PMID: 34941876Ayerdi O, Puerta T, Clavo P, et al. Preventive efficacy of tenofovir/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users. Open Forum Infect Dis 2020; 7(11): ofaa455. doi: 10.1093/ofid/ofaa455 PMID: 33200081Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76(16): 1815-26. doi: 10.1016/j.jacc.2020.08.041 PMID: 32860872